Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.
Stefano GiulianiIrene ParaboschiAngus G K McNairMyles SmithKenneth Samora RankinDaniel S ElsonVinidh PaleriDaniel LeffGraeme StasiukJohn Andersonnull nullPublished in: Cancers (2024)
This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative identification of the tumor margins of extra-hematological solid tumors. For each of them, the targeted antigen, the mAb generic/commercial name and format, and clinical indications are presented, together with utility, doses, and the timing of administration. Based on the current scientific evidence in humans, the top three mAbs that could be prepared in a GMP-compliant bank ready to be delivered for surgical purposes are proposed to speed up the translation to the operating room and produce a few readily available "off-the-shelf" injectable fluorescent probes for safer and more effective solid tumor resection.
Keyphrases
- minimally invasive
- cancer therapy
- clinical trial
- single molecule
- coronary artery bypass
- living cells
- small molecule
- surgical site infection
- drug delivery
- randomized controlled trial
- patients undergoing
- energy transfer
- quantum dots
- escherichia coli
- coronary artery disease
- hyaluronic acid
- open label
- cystic fibrosis
- monoclonal antibody
- pseudomonas aeruginosa
- phase iii